Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374141 | 0.89 | TDP1 (0.46) | CYP3A4TDP1ALDH1A1HPGDGABRA1 | |
| SCHEMBL17775843 | 0.83 | GABRA1 (0.33) | ALDH1A1GABRA1GABRB2GLATSHR | |
| SCHEMBL374359 | 0.74 | ALDH1A1 (0.42) | CYP3A4TDP1ALDH1A1HPGDGABRA1 | |
| SCHEMBL29796039 | 0.72 | ALDH1A1 (0.53) | CYP3A4TDP1ALDH1A1HPGDGLA | |
| SCHEMBL23214234 | 0.72 | ALDH1A1 (0.53) | CYP3A4TDP1ALDH1A1HPGDGLA | |
| SCHEMBL29795909 | 0.72 | GABRA1 (0.39) | CYP3A4TDP1GABRA1GABRB2TRPA1 | |
| SCHEMBL23213592 | 0.72 | GABRA1 (0.39) | CYP3A4TDP1GABRA1GABRB2TRPA1 | |
| SCHEMBL11559627 | 0.71 | CYP3A4 (0.55) | CYP3A4TDP1ALDH1A1HPGDGLA | |
| SCHEMBL17764871 | 0.71 | GABRA1 (0.37) | CYP3A4TDP1ALDH1A1HPGDGABRA1 | |
| SCHEMBL23213549 | 0.71 | GABRA1 (0.38) | CYP3A4TDP1ALDH1A1GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093972-A1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093972-A1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | FGFR4, FGFR1, FGFR3 | CYP3A4 755/4885TDP1 1710/4885ALDH1A1 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.